Subsidiary of ApicHope Pharmaceutical Group (300723.SZ) obtained the registration certificate for Ximiting Injection.

ApicHope Pharmaceutical Group (300723.SZ) announced that its wholly-owned subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. recently received the Drug Registration Certificate for the injection solution of Omeprazole approved and issued by the National Medical Products Administration. The indication for Omeprazole injection solution is for the treatment of gastrointestinal ulcers. Obtaining the registration certificate for Omeprazole injection solution indicates that the company now has the qualification to sell this specification of drug in the domestic market, which will further enrich the company's product pipeline and categories, and enhance its competitiveness in the field of chronic disease medications.